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Abstract 
Background: Polymorphisms in the interferon-λ (IFNL) 3/4 region have been associated with 
reduced hepatitis C virus clearance. We explored the role of such polymorphisms on the 
incidence of CMV infection in solid-organ transplant (SOT) recipients.  
Methods: Caucasian patients participating in the Swiss Transplant Cohort Study in 2008-2011 
were included. A novel functional TT/-G polymorphism (rs368234815) in the CpG region 
upstream of IFNL3 was investigated.  
Results: A total of 840 SOT recipients at risk for CMV were included, among whom 373 (44%) 
received antiviral prophylaxis. The 12-months cumulative incidence of CMV replication and 
disease were 0.44 and 0.08, respectively. Patient homozygous for the minor rs368234815 allele 
(-G/-G) tended to have a higher cumulative incidence of CMV replication (SHR=1.30 [95%CI 
0.97-1.74], P=0.07) compared to other patients (TT/TT or TT/-G). The association was 
significant among patients followed by a preemptive approach (SHR=1.46 [1.01-2.12], 
P=0.047), espe ially in patients receiving an organ from a seropositive donor (D+, SHR=1.92 
[95%CI 1.30-2.85], P=0.001), but not among those who received antiviral prophylaxis 
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(SHR=1.13 [95%CI 0.70-1.83], P=0.6). These associations remained significant in multivariate 
competing risk regression models.  
Conclusions: Polymorphisms in the IFNL3/4 region influence susceptibility to CMV replication 
in SOT recipients, particularly in patients not receiving antiviral prophylaxis. 
 
Background 
Cytomegalovirus (CMV) infection remains one of the most common infectious complications 
after solid-organ transplantation (SOT) (1).  Several risk factors for the development of CMV 
have been described, the donor (D) and recipient (R) serostatus at the time of transplantation 
being the main determinant for predicting the risk for subsequent CMV infection (2). Additional 
risk factors include the type and dose of immunosuppressive drug used and previous occurrence 
of acute rejection (3). Despite advances in the prevention of CMV replication post transplant, a 
significant number of recipients may still develop CMV disease, even in the absence of these 
above mentioned risk factors (4). 
While it is widely accepted that the adaptive immunity is essential in the control of CMV 
replication, particularly the specific CD8+ T cell response against CMV (5), the importance of 
innate immunity for CMV control has not completely been determined (6). After transplantation, 
when cellular immunity is im aired due to the effect of immunosuppressive drugs, innate 
immunity may play a more prominent role in controlling viral replication. For example, some 
studies have identified that polymorphisms of genes involved in innate immunity, such as toll-
like receptors (TLR)-2 (7), TLR-4, and mannose binding lectin (MBL) (8, 9), were associated 
with an increasing incidence of CMV infection or disease after transplantation.  
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Type I interferons (IFN) have been long considered to be critical for immune responses to 
viral infections. However, type III IFNs, also called IFNs-lambda (IFNLs), have recently been 
described to share many biological functions with type I IFN, and also to have an important role 
in response to viral infections (10, 11). In particular, genome-wide association studies (GWAS) 
revealed that polymorphisms in the IFNL3/4 region exert a dramatic influence on the ability to 
clear the hepatitis C virus (HCV), either spontaneously (12), or in response to antivi al therapy 
(12-15). A novel TT/-G substitution (rs368234815) was recently identified as possibly the most 
robust or clinically relevant marker predicting HCV clearance (16, 17). 
The potential influence of IFNLs polymorphisms on controlling viral infection other than 
hepatitis C has not been well characterized. In two recent studies in SOT and in hematopoietic 
stem-cell transplant (HSCT) recipients, the presence of a minor allele of IFNL3 polymorphisms 
was associated with reduced post transplant CMV replication (18, 19). This was in contrast with 
a study involving high-risk HIV-infected individuals, where patients harboring the minor allele 
of rs368234815 had a higher incidence of CMV retinitis (20). We therefore explored here the 
role of this novel IFNL3/4 rs368234815 polymorphism on the incidence of CMV infection and 
disease in a unique nationwide prospective cohort of SOT recipients, the Swiss Transplant 
Cohort Study (STCS). 
 
Methods 
Study population 
The STCS is a multicenter nationwide cohort study including SOT performed in Switzerland 
from May 2008 onward (21). The STCS comprises six transplant centers in Switzerland. Kidney 
transplantation is performed in all centers, liver and heart transplantation in three centers, and 
lung and pancreas transplantation in two centers. Data on demographic parameters, transplant 
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type, comorbidities, immunosuppressive treatment, antimicrobial drugs, rejection, infectious and 
non-infectious events are collected at enrolment, at six months and every 12 months on 
standardized data forms by local physicians and data managers. Specific data on CMV infection 
available in the STCS database include the date of the first episode of CMV replication and of 
each episode of CMV disease, the use of antiviral drugs and the type of CMV event which is 
classified as asymptomatic replication, viral syndrome, and probable or proven end-organ 
disease.  
For the present study, we included all Caucasian patients transplanted from May 2008 to 
March 2011 with at least one post transplant follow-up, a positive donor and/or recipient CMV 
serostatus, DNA available for genotyping and written informed consent for participation in the 
STCS. Patients who died within 24 hours of transplant were excluded. The STCS protocol has 
been approved by the Ethics Committees of all participating centers. 
 
Antiviral and immunosuppressive regimens 
The antiviral preventive strategy per protocol varied among centers and type of transplant (2). 
Most D+/R- patients received valganciclovir prophylaxis for three to six months, except in two 
transplant programs, where patients were followed preemptively. Seropositive (R+) patients were 
managed either by preemptive therapy or antiviral prophylaxis according to the transplant 
program, except for lung transplant recipients who all received antiviral prophylaxis. In patients 
receiving antiviral prophylaxis, monitoring of CMV replication by PCR was done after 
discontinuation of prophylaxis in five out of the six transplant centers every 2-4 weeks for an 
additional 3-month period, irrespectively of the CMV serostatus. The protocol of the preemptive 
approach was decided by each center, but basically consisted of screening for CMV DNAemia 
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by PCR every one to two weeks during the first month post transplant and then every two weeks 
until three to six months post transplant. Five centers used PCR in plasma and one center used 
PCR in whole blood. All centers used a home-made PCR, except one center which used a 
commercial Abbott RealTime CMV Assay. Antiviral therapy in asymptomatic patients with 
CMV replication was generally started at a cut-off of 2-3 log10 copies/ml of plasma or 3-4 log10 
copies/ml in whole blood, but this cut-off varied according to the CMV serostatus, time post 
transplant, and whether the patient had received lymphocyte-depleting antibodies or not. Only 
results of the first positive CMV DNAemia (and whether DNAemia was treated or not) were 
recorded in the STCS database. Immunosuppressive regimens also varied among centers and 
type of organ transplant. 
 
IL28B genotyping 
The rs368234815 polymorphism was genotyped by Competitive Allele Specific PCR (KASP™) 
system (LGC Genomics, UK), using the ABI 7500 Fast real time thermocycler, according to 
manufacturer’s protocols (http://www.lgcgenomics.com/kaspchallenge). The KASP primers 
were designed by Kraken™ assay design and workflow management software (LGC Genomics, 
UK). Automated allele calling was performed using SDS software (Applied Biosystems). 
 
Clinical definitions 
Antiviral prophylaxis was defined as the use of ganciclovir or valganciclovir started during the 
first two weeks post transplantation. Patients without such a prophylactic treatment who were at 
risk for CMV disease (D+/R- and R+ patients) were considered as being managed by the 
preemptive approach (2). Definition of CMV infection followed international guidelines (22) 
 at Fachbereichsbibliothek on N
ovem
ber 5, 2014
http://jid.oxfordjournals.org/
D
ow
nloaded from
 
Ac
ce
pte
d M
an
us
cri
pt
8 
defining active CMV infection as the evidence of laboratory confirmation of CMV replication 
irrespectively of symptoms, and CMV disease as CMV replication with corresponding signs and 
symptoms.  
 
Statistical analysis 
The main endpoint of the study was the incidence of CMV replication (thus including 
asymptomatic CMV infection and CMV disease). The cumulative incidence of CMV replication 
by genetic variables was calculated by using the stcompet program implemented in Stata 
(StataCorp LP, College Station, Texas, US). The risk of CMV replication and/or disease for each 
genetic and demographic variable was assessed by using a semi-parametric regression model 
(23), also implemented in Stata (stcrreg). Death was considered a competing event. Stepwise 
multivariate regression model (P<0.1) was used to determine the independent risk factors from 
the predicted variables. We analyzed the incidence of CMV replication in all SOT recipients and 
in kidney transplant recipients.  
 
Results 
Study population 
The characteristics of 840 patients meeting the inclusion criteria are shown in Table 1.  
Overall, 373 (44 %) patients received antiviral prophylaxis, either with valganciclovir upfront or 
initially with IV ganciclovir. Most patients received induction therapy with either basiliximab 
(60%) or anti-thymocyte globulins (18%) and a maintenance immunosuppressive regimen 
including a calcineurin inhibitor, an antimetabolite, and corticosteroids. The 12-months 
cumulative incidence of CMV infection and disease were 0.44 and 0.08, respectively.  Median 
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time from transplant to CMV replication was longer in patients who received prophylaxis than in 
patients followed by the preemptive approach (median of 167 days vs. 40 days, P<0.0001). 
Baseline characteristics in kidney transplant recipients (n=526) were similar as in the whole 
study population (n=840). 
 
Impact of the rs368234815 polymorphism on CMV replication according to antiviral strategy 
Overall, 102 (12%) SOT recipients were homozygous for the minor allele of rs368234815 (-G/-
G carriers). The cumulative incidence of CMV replication tended to be higher among -G/-G 
carriers (0.52) compared to other patients (TT/TT or TT/-G carriers, 0.43, SHR=1.30 [%95 CI 
0.97-1.74], P=0.07, Figure 1 and Table 2). The association was significant when considering 
patients followed by the preemptive approach (SHR 1.46 [95% CI 1.01-2.12], P=0.047), but not 
when considering those who received antiviral prophylaxis (SHR=1.13 [%95 CI 0.72-1.78], 
P=0.6). The former association was still significant in a multivariate model (SHR 1.57 [95% CI 
1.10-2.23], P=0.01) (Table 3), after adjustment for other risk factors associated with CMV 
replication in SOT recipients not receiving prophylaxis, including recipient age, donor/recipient 
CMV serostatus, transplanted organ type, as well as induction and maintenance immuno-
suppressive regimen.  In patients with asymptomatic CMV replication, the presence of the minor 
allele of rs368234815 had no influence on the rate of patients who required antiviral therapy 
(p=0.5). 
Results were similar when kidney transplant recipients were analyzed separately. Among 
kidney recipients followed by a pre-emptive approach, -G/-G carriers had a higher cumulative 
incidence of CMV replication compared to TT/TT and TT/-G carriers (SHR=1.76 [95% CI 1.10-
2.84], P=0.02, Figure 1). This association was still observed in the multivariate analysis, where -
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G/-G carriage was still associated with CMV replication (SHR 1.78 [95% CI 1.18-2.69], 
P=0.006, not shown). However, no association between rs368234815 polymorphism and CMV 
replication was detected among kidney recipients receiving antiviral prophylaxis (SHR 1.11 
[95% CI 0.65 -1.89], P=0.7, not shown). 
There was no association between the rs368234815 polymorphism and CMV disease in 
SOT recipients (-G/-G vs TT/TT and TT/-G, P=0.4) and in kidney transplant recipients (P=1.0, 
Supplementary Figure 1). 
 
Impact of the rs368234815 polymorphism on CMV replication according to CMV serostatus 
We also analyzed the role of the rs368234815 separately according to CMV serostatus. Among 
D+ SOT and kidney transplant recipients who were followed by a preemptive approach, -G/-G 
carriers had a higher cumulative incidence of CMV replication compared to the other patients 
(all patients SHR=1.92 [95%CI 1.30-2.85], P=0.001 and kidney recipients SHR=2.28 [95%CI 
1.40-3.71], P=0.0009 , Figure 2). These association remained significant in the multivariate Cox 
regression models, after adjustment for relevant covariates (SHR=2.06 [95% CI 1.40-3.01], 
P<0.0001 and SHR=2.24 [95% CI 1.40-3.58, P=0.001, respectively; Supplementary Table S1). 
Again, no significant associations were observed among patients receiving antiviral prophylaxis 
(P=0.053 and P=0.2, respectively, Figure 2). 
 
Discussion 
In this nationwide cohort study of SOT recipients, we assessed the potential influence of 
polymorphisms in the IFNL3/4 region on the incidence of CMV replication. We found that the 
TT/-G rs368234815 substitution, which was recently identified as the best predictor of HCV 
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clearance (16, 17), was an independent risk factor for developing CMV replication, specifically 
in the group of patients not receiving antiviral prophylaxis. This was also found for kidney 
transplant recipients in particular, a more homogeneous group of SOT recipients in terms of 
immunosuppression and antiviral strategies. We did not observe any difference in the 
development of CMV disease in patients with or without rs368234815, probably due to the 
overall low incidence of CMV disease in our cohort. 
While extensive literature exists on the role of IFNL3/4 polymorphisms in influencing 
spontaneous or treatment-induced clearance of HCV (12, 13, 15), there are few data assessing a 
potential association between such polymorphisms and CMV replication, particularly in the 
transplant setting. In a recent study of 151 HSCT recipients, donor carriage of the minor TT 
genotype of IFNL3 rs12979860 SNP (a SNP in strong linkage disequilibrium with rs368234815) 
was associated with a shorter duration of CMV replication in the recipient  (18). However, no 
differences in the overall incidence of CMV infection were observed according to this SNP. In a 
study of 38 D+R- SOT recipients, the minor G allele of  rs8099917 (which is also in linkage 
disequilibrium with rs368234815) was associated with lower risk of CMV replication after 
discontinuation of antiviral prophylaxis (19). Finally, in concordance to our data, we found that 
the same rs368234815 polymorphism was significantly associated with the occurrence of CMV 
retinitis in a cohort of 1217 of HIV-infected individuals at risk (HR=2.54, 95% confidence 
interval 1.20-5.40, P=0.02) (20). Discrepancies between studies may be explained by several 
factors, including the use of different study populations and/or groups at risk, and the different 
sample size.  
The exact mechanisms by which rs368234815 may influence susceptibility to CMV 
replication among SOT recipients receiving no antiviral prophylaxis are not well established. 
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However, increasing evidence suggests that IFNLs contribute to antiviral responses against 
viruses other than HCV. The antiviral activity of IFNLs was highlighted in a series of cell culture 
models, including herpesviruses (24-27). In an intestinal cell model of CMV infection, IFNL1 
and IFNL3 were shown to activate STAT1, thereby inducing the production of antiviral proteins 
and inhibiting the expression of CMV (28). The administration of recombinant IFNLs inhibited 
replication in mice models of HSV infections (26), thereby confirming the role of these 
molecules in vivo. However, blockade of the IL28 R1 subunit of the IL28B receptor was recently 
reported to decrease CMV replication in foreskin fibroblast (19). The rs368234815 
polymorphism was associated with reduced HCV clearance in PBMCs stimulated with poly(I:C) 
(17). It was also associated with the expression of a novel IFNL analogue, named IFNL4, that 
exerts antiviral activities similar to those of other type I and type III IFNs in vitro (16, 29). 
Therefore, increased CMV events among SOT recipient carrying the rs368234815 may be due in 
part to insufficient IFNL3 expression, or to the expression of IFNL4 itself. Yet, the reason why 
the expression of IFNL4 would be associated with increased rather than decreased viral 
replication in vivo remains to be elucidated (30). In a mouse model of lymphocytic 
choriomeningitis virus (LCMV), differences in the IFN-stimulated genes background were 
observed in acute vs. latent infection, determining the control of LCMV replication (31). Further 
investigations are needed to understand the exact role of IFNL3 and IFNL4 in antiviral immune 
responses. 
 An important finding of our study is that the influence of IFNL3/4 polymorphism on 
CMV replication disappeared when considering patients receiving CMV prophylaxis. A 
plausible hypothesis is that, in patients managed by the preemptive approach, CMV replication 
develops earlier and more frequently after transplant than in patients receiving antiviral 
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prophylaxis. As cell-mediated immunity is impaired after transplant, the role of innate immunity 
might be more evident when viral replication occurs early and more often after transplant. This is 
in concordance with previous studies evaluating the role of NK immunoglobulin-like receptor 
(KIR) polymorphisms, in which the influence of such polymorphisms in determining CMV 
replication was significant also during the first three months post transplant, but decreased over 
time (32). We also found that donor CMV serostatus was more important in determining the 
influence of the IFNL variants than recipient CMV serostatus. Actually, the wide majority of 
patients harboring the rs368234815 polymorphism having received an organ from a seropositive 
donor developed CMV replication independently whether they were R- or R+. These data 
suggest that new CMV strains transmitted by the donor (33) may be more difficult to control in 
recipients harboring the rs368234815 polymorphism. 
  Our study has some limitations. First, because only the first episode of asymptomatic 
CMV replication was collected on the STCS database, we were not able to investigate in the 
present study whether the IFNL3/4 polymorphisms had an impact on the overall duration of 
CMV infection and particularly on the response to antiviral therapy. Second, patients who 
received antiviral therapy were not monitored for CMV replication using the same schedule than 
patients managed by the preemptive approach just after transplantation; this difference could 
partially account for the different impact of the IFNL3/4 polymorphisms on CMV replication 
observed according to the preventive strategy used.  Third, the low number of CMV disease 
events prevented to extract any conclusion about a potential higher risk of progression from 
asymptomatic viral replication to overt CMV disease in patients with -G/-G carriage. Fourth, the 
association between CMV replication and IFNL3 polymorphism was observed for the recessive 
mode of inheritance, while the association observed among HCV infected patients is usually 
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dominant. This difference may be due to some threshold effect of the amount of IFNL3/4 in 
response to specific pathogens. Because the recessive model was chosen in a post-hoc analysis, 
this could also account as a limitation of our study. Finally, the prevention strategies and 
immunosuppressive regimens were somewhat variable among transplant programs, so that it is 
possible that some remaining biases specifically related to the transplant center were not 
corrected by the multivariate analysis. Nevertheless, because of the large number of patients 
included, the strict and homogeneous definitions used for CMV infection, and the use of a novel 
polymorphism with predicted functional activity, the data indicate novel evidence of a 
relationship between IFNL polymorphisms and CMV infection. 
 In conclusion, in this large cohort of SOT recipients, we found that CMV infection in 
patients not receiving antiviral prophylaxis was influenced by IFNL genetic variants. This effect 
was stronger in recipients who received an allograft from a CMV seropositive donor.  These 
results indicate that the INFL rs368234815 polymorphism might be considered as a novel risk 
factor for developing CMV complications after organ transplantation. Validation of this 
association in further clinical studies has the potential to lead a better risk stratification for CMV 
reactivation and eventually influence future prevention strategies and guidelines, particularly in 
those patients followed by the preemptive approach. 
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Table 1. Baseline patient’s characteristics 
Variable D+/R- or R+ SOT 
recipients 
N=8401 
D+/R- or R+ kidney 
transplant recipients 
N=526 
Recipient age (median years; IQR) 54 (18) 54 (20) 
Donor age (median years; IQR) 2 53 (22) 53 (20) 
Recipient sex M/F (%) 534/306 (64/36) 336/191 (64/36) 
Caucasian ethnicity 840 (100) 526(100) 
Transplanted organ (%)   
Kidney 493 (59) 493 (94) 
Liver 163 (19) - 
Lung 78 (9) - 
Heart 56 (7) - 
Pancreas / islets /small bowel 3 17 (2) - 
Combined 4 33 (4) 33 (6) 
Donor type (%)   
Deceased 629 (75) 325 (62) 
Living related and unrelated 211 (25) 201 (38) 
HLA full mismatch (%) 5 294 (59) 209 (52) 
CMV serostatus (%)   
D+/R- 218 (26) 134 (26) 
D-/R+ 263 (31) 159 (30) 
D+/R+ 359 (43) 235 (44) 
Induction therapy (%) 6   
Basiliximab 488 (60) 308 (62) 
Anti-thymocyte globulin  143 (18) 88 (18) 
None 179 (22) 103 (21) 
Maintenance regimen (%) 7   
Tacrolimus 495 (65) 379 (77) 
Ciclosporine 205 (27) 100 (20) 
MMF/MPA 616 (81) 429 (87) 
Azathioprine 22 (3) 16 (3) 
mTOR inhibitors 52 (7) 11 (2) 
Corticosteroids 517 (68) 366 (74) 
CMV management approach   
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1  Among 1119 Caucasian individuals enrolled in the STCS genetic study, 279 were excluded because they had both 
a donor and recipient negative CMV serostatus (D-R-, N=253), had a missing/incomplete CMV serology (N=13), 
died within 24 hours of transplant (N=7) or had a missing IFNL3/4 genotype (N=6). 
2  Donor age was missing in 163 solid organ transplant recipients and 0 kidney recipients. 
3  Including 12 islet, 4 pancreas and 1 small bowel transplants. 
4 Including 19 kidney-pancreas, 6 kidney-liver, 4 kidney-kidney, 2 kidney-islets, 1 kidney-lung and 1 kidney-kidney-
pancreas transplants. 
5 Data were missing in 341 SOT recipients and 124 kidney transplant recipients, respectively 
6 Data were missing in 30 SOT recipients and 27 kidney transplant recipients, respectively 
7 Treatment at 12 months was assessable in 763 SOT recipients and 494 kid ey transplant recipients, respectively 
 
Abbreviations: CMV: cytomegalovirus; D: donor; IQR: interquartile range; MMF: mycophenolate mofetil; MPA: 
mycophenolic acid; R: recipient. 
prophylaxis (%) 373 (44) 248 (47) 
pre-emptive (%) 467 (56) 278 (53) 
Acute rejection episode (12-months 
cumulative incidence) 
259 (31) 134 (25) 
CMV infection (12-months cumulative 
incidence) 
0.44 0.47 
CMV disease (12-months cumulative 
incidence) 
0.08 0.08 
IFNL3/4 -G/-G 102 (12) 61 (12) 
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Table 2. Univariate analysis of risk factors for the development of CMV replication in 
CMV D+/R- or R+ SOT recipients and in patients not receiving antiviral prophylaxis   
 
Variable All patients (N=840)
 
 
Patients not receiving antiviral 
prophylaxis (N=467) 
 
 SHR (95% CI)1 P-value SHR (95% CI)1 P-value
Recipient age (per 10 years) 1.12 (1.04-1.21) 0.003 1.11 (1.01-1.22) 0.02
Donor age (years) 1.03 (0.96-1.11) 0.4 1.05 (0.96-1.14) 0.3 
Recipient male sex 0.97 (0.79-1.20) 0.8 0.99 (0.75-1.31) 1.0 
Transplanted organ     
Kidney Ref.  Ref.  
Liver 0.79 (0.58-1.07) 0.13 0.58 (0.41-0.82) 0.002
Other/combined 0.83 (0.64-1.07) 0.15 0.85 (0.58-1.24) 0.4 
HLA full mismatch 1.17 (0.90-1.52) 0.2 1.15 (0.82-1.62) 0.4 
Rejection episode 1.05 (1.01-1.09) 0.007 1.04 (0.98-1.11) 0.18 
CMV serostatus     
D+/R- Ref.  Ref.  
D-/R+ 0.81 (0.61-1.08) 0.15 0.85 (0.54-1.32) 0.5 
D+/R+ 1.33 (1.04-1.69) 0.02 1.53 (1.03-2.28) 0.04
Induction therapy     
None Ref.  Ref.  
Basiliximab  1.03 (0.78-1.35) 0.9 1.15 (0.83-1.58) 0.4 
Anti-thymocyte globulin  1.19 (0.86-1.65) 0.3 1.99 (1.29-3.08) 0.002
Maintenance regimen     
Tacrolimus 0.97 (0.94-1.01) 0.13 0.94 (0.87-1.00) 0.06 
Ciclosporine 1.05 (1.01-1.08) 0.01 1.09 (1.01-1.17) 0.02
MMF/MPA 1.08 (1.02-1.14) 0.009 1.10 (0.99-1.22) 0.08 
mTOR inhibitors 0.99 (0.90-1.09) 0.8 0.97 (0.83-1.14) 0.7 
Corticosteroids 1.12 (1.04-1.21) 0.003 1.33 (1.01-1.76) 0.04
Exposure to antiviral drug2 0.90 (0.81-0.99) 0.02 0.96 (0.78-1.18) 0.7 
IFNL3/4 -G/-G3 1.30 (0.97-1.74) 0.07 1.46 (1.01-2.12) 0.047
 
1  SHR stands for the subdistribution hazard ratio (calculated by using semi-parametric regression model of Fine and 
Gray (23)) 
 
2  Risk of CMV infection during concurrent exposure to valganciclovir or ganciclovir 
 
3  Genetic association with rs368234815 is for recessive mode of inheritance (patients homozygous for the rare 
alleles (-G/-G) are compared to the other [TT/TT and TT/-G]) 
 
Abbreviations: CI: confidence interval; CMV: cytomegalovirus; SHR: subdistribution hazard ratio; IFNL3/4: interferon 
lambda 3/4. MMF: mycophenolate mofetil; MPA: mycophenolic acid
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Table 3. Multivariate analysis of risk factors for the development of CMV replication in all 
CMV D+/R- or R+ SOT recipients and in patients not receiving antiviral prophylaxis 
 
 All patients (N=840)
 
 
Patients not receiving 
antiviral prophylaxis (N=455)1 
 
 SHR (95% CI)2 P-value SHR (95% CI)2 P-value
Recipient age (per 10 years) 1.14 (1.06-1.23) 0.001 1.12 (1.02-1.24) 0.02
Transplanted organ     
Kidney   Ref.  
Liver  0.66 (0.45-0.98) 0.04
Other/combined  0.66 (0.42-1.04) 0.07 
CMV serostatus     
D+/R- Ref.  Ref.  
D-/R+ 0.75 (0.56-1.01) 0.06 0.91 (0.55-1.49) 0.7 
D+/R+ 1.29 (0.01-1.70) 0.04 1.60 (1.02-2.60) 0.04
Induction therapy     
None   Ref.  
Basiliximab    1.14 (0.82-1.58) 0.5 
Anti-thymocyte globulin    2.08 (1.21-3.57) 0.008
Acute rejection 1.05 (1.02-1.09) 0.005  
Maintenance therapy     
Corticosteroids 1.13 (1.04-1.22) 0.003 1.31 (1.01-1.70) 0.04
Tacrolimus  0.91 (0.84-0.99) 0.02
MMF/MPA 1.07 (1.01-1.13) 0.02  
Cyclosporine 1.08 (1.04-1.12) <0.0001  
Exposure to antiviral drug3 0.85 (0.77-0.93) 0.001  
IFNL3/4 -G/-G4 1.32 (0.99-1.75) 0.06 1.57 (1.10-2.23) 0.01
 
1  The number of patients in the multivariate analyses (N=455) is slightly lower than the number of patients included in 
the univariate analysis (N=467) due to missing data for induction therapy in 12 patients. 
 
2  SHR stands for the subdistribution hazard ratio (calculated by using semi-parametric regression model of Fine and 
Gray (23)). Covariates with a P value <0.1 were kept in the multivariate analyses. 
 
3  Risk of CMV infection during concurrent exposure to valganciclovir or ganciclovir. 
 
4  Genetic association with rs368234815 is for recessive mode of inheritance (patients homozygous for the rare 
alleles (-G/-G) are compared to the other (TT/TT and TT/-G)). 
 
Abbreviations: CI: confidence interval; CMV: cytomegalovirus; SHR: subdistribution hazard ratio; IFNL3/4: interferon 
lambda 3/4. 
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Legend Figure 1. Cumulative incidence of CMV replication according to prophylaxis and 
transplanted organ in patients homozygous for the minor allele of rs368234815 (-G/-G 
carriers) vs. TT/TT or TT/-G carriers. A semi-parametric regression model of Fine and Gray 
(23) was used to evaluate the relative hazards associated with the demographic factors or genetic 
variants and the endpoints. N indicates the number of patients with CMV infection in each group 
of patients. 
Legend Figure 2. Cumulative incidence of CMV replication according to antiviral 
preventive strategy in D+ SOT recipients and in kidney transplant recipients in patients 
homozygous for the minor allele of rs368234815 (-G/-G carriers) vs. TT/TT or TT/-G 
carriers. A semi-parametric regression model of Fine and Gray (23) was used to evaluate the 
relative hazards associated with the demographic factors or genetic variants and the endpoints. N 
indicates the number of patients with CMV infection in each group of patients. 
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